Benjamin J. Ansell

5.0k total citations · 2 hit papers
33 papers, 3.9k citations indexed

About

Benjamin J. Ansell is a scholar working on Surgery, Endocrinology, Diabetes and Metabolism and Economics and Econometrics. According to data from OpenAlex, Benjamin J. Ansell has authored 33 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 27 papers in Surgery, 23 papers in Endocrinology, Diabetes and Metabolism and 7 papers in Economics and Econometrics. Recurrent topics in Benjamin J. Ansell's work include Lipoproteins and Cardiovascular Health (26 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (22 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). Benjamin J. Ansell is often cited by papers focused on Lipoproteins and Cardiovascular Health (26 papers), Diabetes, Cardiovascular Risks, and Lipoproteins (22 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). Benjamin J. Ansell collaborates with scholars based in United States, Australia and France. Benjamin J. Ansell's co-authors include Alan M. Fogelman, Gregg C. Fonarow, Mohamad Navab, Srinivasa T. Reddy, Inder M. Singh, Mehdi H. Shishehbor, Greg Hough, Susan Hama, Naeimeh Kamranpour and Brian J. Van Lenten and has published in prestigious journals such as New England Journal of Medicine, JAMA and Circulation.

In The Last Decade

Benjamin J. Ansell

32 papers receiving 3.8k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dysfunctional HDL and atherosclerotic cardiovascular disease

2015 567 citations Robert S. Rosenson, H. Bryan Brewer et al. Nature Reviews Cardiology profile →
Thematic review series: The Pathogenesis of Atherosclerosis The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL

2004 546 citations Mohamad Navab, Srinivasa T. Reddy et al. Journal of Lipid Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Benjamin J. Ansell United States	22	1.9k	1.6k	711	613	560	33	3.9k
Francisco Blanco‐Vaca Spain	41	2.3k 1.2×	1.3k 0.8×	676 1.0×	1.5k 2.4×	730 1.3×	178	5.5k
John R. Burnett Australia	36	2.5k 1.3×	1.3k 0.8×	956 1.3×	1.3k 2.1×	694 1.2×	164	4.6k
Jerzy–Roch Nofer Germany	36	2.0k 1.0×	1.3k 0.8×	723 1.0×	2.0k 3.3×	628 1.1×	104	5.0k
Ulrich Julius Germany	28	1.5k 0.8×	1.5k 0.9×	735 1.0×	548 0.9×	257 0.5×	173	3.6k
P. Barton Duell United States	33	2.6k 1.3×	1.0k 0.6×	745 1.0×	619 1.0×	505 0.9×	114	4.7k
Leiv Ose Norway	43	3.6k 1.9×	1.6k 0.9×	910 1.3×	866 1.4×	1.0k 1.8×	161	5.8k
José Luís Sánchez-Quesada Spain	36	1.3k 0.7×	960 0.6×	541 0.8×	661 1.1×	325 0.6×	144	3.5k
Eleni Bairaktari Greece	36	1.4k 0.7×	1.1k 0.7×	517 0.7×	946 1.5×	501 0.9×	146	3.9k
Marina Cuchel United States	26	3.3k 1.7×	2.3k 1.4×	1.2k 1.8×	969 1.6×	1.2k 2.1×	81	5.0k
Alexandros D. Tselepis Greece	46	3.2k 1.7×	2.1k 1.3×	1.5k 2.1×	1.3k 2.1×	983 1.8×	258	7.3k

Countries citing papers authored by Benjamin J. Ansell

Since Specialization

Citations

This map shows the geographic impact of Benjamin J. Ansell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Benjamin J. Ansell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Benjamin J. Ansell more than expected).

Fields of papers citing papers by Benjamin J. Ansell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Benjamin J. Ansell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Benjamin J. Ansell. The network helps show where Benjamin J. Ansell may publish in the future.

Co-authorship network of co-authors of Benjamin J. Ansell

This figure shows the co-authorship network connecting the top 25 collaborators of Benjamin J. Ansell. A scholar is included among the top collaborators of Benjamin J. Ansell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Benjamin J. Ansell. Benjamin J. Ansell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Rosenson, Robert S., H. Bryan Brewer, Benjamin J. Ansell, et al.. (2015). Dysfunctional HDL and atherosclerotic cardiovascular disease. Nature Reviews Cardiology. 13(1). 48–60. 567 indexed citations breakdown →

Ansell, Benjamin J.. (2008). Not Getting to Goal: The Clinical Costs of Noncompliance. Journal of Managed Care Pharmacy. 14(6 Supp B). 9–15. 16 indexed citations

Ansell, Benjamin J.. (2008). A review of trials evaluating nonstatin lipid-lowering therapies. Current Atherosclerosis Reports. 11(1). 64–66. 1 indexed citations

Hahn, Bevra H., Jennifer Grossman, Benjamin J. Ansell, Brian J. Skaggs, & Maureen McMahon. (2008). Altered lipoprotein metabolism in chronic inflammatory states: proinflammatory high-density lipoprotein and accelerated atherosclerosis in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Research & Therapy. 10(4). 213–213. 78 indexed citations

Ansell, Benjamin J.. (2007). Targeting the Anti-Inflammatory Effects of High-Density Lipoprotein. The American Journal of Cardiology. 100(11). S3–S9. 28 indexed citations

Singh, Inder M., Mehdi H. Shishehbor, & Benjamin J. Ansell. (2007). High-Density Lipoprotein as a Therapeutic Target. JAMA. 298(7). 786–786. 350 indexed citations

Ansell, Benjamin J., Gregg C. Fonarow, & Alan M. Fogelman. (2007). The paradox of dysfunctional high-density lipoprotein. Current Opinion in Lipidology. 18(4). 427–434. 157 indexed citations

Ansell, Benjamin J.. (2007). The two faces of the 'good' cholesterol.. Cleveland Clinic Journal of Medicine. 74(10). 697–700. 22 indexed citations

Navab, Mohamad, G.M. Anantharamaiah, Srinivasa T. Reddy, et al.. (2006). Mechanisms of Disease: proatherogenic HDL—an evolving field. Nature Clinical Practice Endocrinology & Metabolism. 2(9). 504–511. 195 indexed citations

10.

Ansell, Benjamin J., Gregg C. Fonarow, & Alan M. Fogelman. (2006). High-density lipoprotein: Is it always atheroprotective?. Current Atherosclerosis Reports. 8(5). 405–411. 66 indexed citations

11.

Ansell, Benjamin J., Gregg C. Fonarow, Kevin C. Maki, et al.. (2006). Reduced treatment success in lipid management among women with coronary heart disease or risk equivalents: Results of a national survey. American Heart Journal. 152(5). 976–981. 31 indexed citations

12.

Navab, Mohamad, Srinivasa T. Reddy, Brian J. Van Lenten, et al.. (2005). The double jeopardy of HDL. Annals of Medicine. 37(3). 173–178. 116 indexed citations

13.

Ansell, Benjamin J.. (2005). Rationale for combination therapy with statin drugs in the treatment of dyslipidemia. Current Atherosclerosis Reports. 7(1). 29–33. 12 indexed citations

14.

Davidson, Michael H., Kevin C. Maki, Thomas A. Pearson, et al.. (2005). Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II Survey and Implications for Treatment Under the Recent NCEP Writing Group Recommendations. The American Journal of Cardiology. 96(4). 556–563. 232 indexed citations

15.

Navab, Mohamad, Srinivasa T. Reddy, Brian J. Van Lenten, et al.. (2004). Thematic review series: The Pathogenesis of Atherosclerosis The oxidation hypothesis of atherogenesis: the role of oxidized phospholipids and HDL. Journal of Lipid Research. 45(6). 993–1007. 546 indexed citations breakdown →

16.

Ansell, Benjamin J., Mohamad Navab, Karol E. Watson, Gregg C. Fonarow, & Alan M. Fogelman. (2004). Anti-Inflammatory Properties of HDL. Reviews in Endocrine and Metabolic Disorders. 5(4). 351–358. 42 indexed citations

17.

Ansell, Benjamin J., Karol E. Watson, Robert E. Weiss, & Gregg C. Fonarow. (2003). hsCRP and HDL Effects of Statins Trial (CHEST): Rapid Effect of Statin Therapy on C-Reactive Protein and High-Density Lipoprotein Levels. PubMed. 5(1). 2–7. 43 indexed citations

18.

Ansell, Benjamin J.. (2002). Future directions in lipid therapies. Advances in Therapy. 19(2). 61–72. 6 indexed citations

19.

Ansell, Benjamin J.. (2000). Cholesterol, stroke risk, and stroke prevention. Current Atherosclerosis Reports. 2(2). 92–96. 30 indexed citations

20.

Ansell, Benjamin J.. (1999). An Evidence-Based Assessment of the NCEP Adult Treatment Panel II Guidelines. JAMA. 282(21). 2051–2051. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact